SELECTBIO - Stem Cells in Drug Discovery 2016 Biographies

Home

Agenda

Keynote Speakers

Registration

Exhibition

Venue

Rising to the Challenges of Human iPSC-derived Cells For Tox & Drug Screening

Tuesday, 5 April 2016 at 10:15

Add to Calendar ▼2016-04-05 10:15:002016-04-05 11:15:00Europe/LondonRising to the Challenges of Human iPSC-derived Cells For Tox and Drug ScreeningStem Cells in Drug Discovery 2016 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com

We will present 'in the field' data on our portfolio of human iPSC and primary cells demonstrating their proven ease of use, reliability and consistency as meaningful drug discovery tools. Here, we overcome the challenges of cell line variability and address the needs for cell scale-up in assay campaigns.

Paul Bello, Director of Operations, Axol Bioscience

Paul Bello joined Axol Bioscience Ltd. In March 2016 and responsible for leading the company's site operations, as well as contributing to international research and business efforts. Paul earned his PhD in 1993 at the Centre for Animal Biotechnology, Melbourne University, Australia, and his background covers over 30 years based in human stem cell R&D, product development and commercialisation, as well as cell automation platforms for drug discovery. More recently, he led facility operations management, partnering and contract technology transfer, and regulatory requirements at a number of stem cell biotechnology SMEs.